The health of our planet and its people are inextricably linked. Climate change and poor air quality resulting from burning fossil fuels can adversely impact human health. Given Gilead’s vision to make the world a healthier place for all people, we feel an obligation to be part of the solution. Our strategy is to set ambitious environmental targets and put programs in place to address the four focus areas that guide our comprehensive approach to sustainability: Carbon, Water, Waste and Product. We have set bold science-based greenhouse gas emissions reduction targets for our own operations and for our value chain. And we’re engaging with suppliers to achieve them. We’re taking measures to reduce our energy and water use, drive waste and inefficiencies from our manufacturing processes and operations, and to embrace green buildings. At Gilead, making the world a healthier place for all people starts with delivering innovative therapies. Our ambitions have led to a cure for hepatitis C, and we are leading the charge to help end the HIV epidemic for everyone, everywhere, by helping to transform treatment and prevention of HIV. We work to provide patients with world-class science, including new antiviral therapies, next-generation cancer treatments and medicines for inflammatory diseases. Our work in cell therapy has led to transformational outcomes for patients with lymphomas and other B-cell malignancies. Innovative science, however, is just the start. Gilead has long been committed to addressing the social determinants of health and overcoming barriers to care. Through our many global and local partnerships, we strive to advance health equity, diversity in clinical trials and access to medicines to reduce disparities, advance education among healthcare professionals and support the local communities in which we operate.Our management establishes and maintains robust internal controls that govern our tax policies and financial reporting procedures, including management of associated risks. Under this system, key tax processes are reviewed by our internal and external auditors for adherence. Our Chief Financial Officer and Board Audit Committee receive updates on at least a quarterly basis. Despite our strong governance, a level of risk associated with tax compliance naturally exists because tax law is inherently complex and can result in a variety of interpretations with respect to how our operations are taxed. Our tax processes and procedures are designed to mitigate such material tax risks. Among other processes and procedures, transactions between our affiliated companies are guided by the arm’s length standard as set out by the Organisation for Economic Co-operation and Development (OECD) guidelines for international tax matters. All material tax planning proposals are discussed with and approved by our executive management, Chief Financial Officer, and the Board Audit Committee. Where appropriate, we seek high-quality external advice on tax consequences of business transactions.Gilead is known for its antiviral drugs and therapeutic treatments, particularly in areas like HIV, hepatitis, and more recently, COVID-19. The company’s ability to innovate and develop new treatments is a key factor in its financial sustainability. Gilead’s revenue is driven by demand for its antiviral drugs and therapies, contributing to its financial stability.To determine our ESG focus areas, Gilead conducted an ESG Materiality Assessment in 2020. Business leaders from across the company selected material topics for our ESG program based on the degree to which Gilead could influence these topics internally and externally, our relative impact, peer evaluations and due diligence. We regularly re-evaluate how we report on material topics and plan to refresh our ESG materiality in 2024 including through the lens of double materiality. Everything we do at Gilead is built upon on a solid foundation of corporate governance, unwavering ethics and the principles of belonging and inclusion.